A new drug reduces airway hyperreactivity in asthma patients
Official title: Protein display drug ANDI reduces asthmatic airway hyperreactivity
Funded at Aaiit LLC · NIH-11175827 · Data updated 2026-11-12
This study is testing a new drug called ANDI that helps people with severe allergic asthma by targeting and removing certain antibodies that cause inflammation, with the goal of making it easier for them to breathe and reducing asthma attacks.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aaiit LLC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $320,863 |
| NIH project number | 1R43AI186551-01A1 |
| Project ID | NIH-11175827 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from severe allergic asthma who have not achieved adequate control with existing treatments.
✕Less likely to help
Patients with non-allergic asthma or those who do not have elevated IgE levels may not benefit from this research.
What this research studies
This research investigates a novel drug called ANDI, which targets and removes IgE antibodies bound to mast cells, a key factor in severe allergic asthma. By dissociating these antibodies, the drug aims to reduce inflammation and improve lung function in asthmatic patients. The study will involve assessing the drug's effectiveness in reducing asthma exacerbations and improving overall respiratory health. Patients may be monitored for changes in their symptoms and lung function during the treatment period.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for asthma, potentially reducing symptoms and improving quality of life for patients.
How similar studies have gone: Previous research has shown promise with similar approaches targeting IgE in asthma treatment, but this specific drug is a novel development.
Where this research is happening
-
Aaiit LLC
San Diego, United States Active
Researchers
- Principal investigator: Chen, Swey-Shen — Aaiit LLC
- Study coordinator: Chen, Swey-Shen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.